Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00383474
Status:
COMPLETED
Last Update Posted:
2015-04-15
First Post:
2006-09-29
Brief Title:
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Untreated Adult Acute Myeloid Leukemia |
| Adult Acute Basophilic Leukemia |
| Adult Acute Eosinophilic Leukemia |
| Adult Acute Megakaryoblastic Leukemia |
| Adult Acute Monoblastic Leukemia |
| Adult Acute Monocytic Leukemia |
| Adult Acute Myeloid Leukemia With Inv16p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With Maturation |
| Adult Acute Myeloid Leukemia With Minimal Differentiation |
| Adult Acute Myeloid Leukemia With t1616p131q22 CBFB-MYH11 |
| Adult Acute Myeloid Leukemia With t821q22q22 RUNX1-RUNX1T1 |
| Adult Acute Myeloid Leukemia With t911p22q23 MLLT3-MLL |
| Adult Acute Myeloid Leukemia Without Maturation |
| Adult Acute Myelomonocytic Leukemia |
| Adult Erythroleukemia |
| Adult Pure Erythroid Leukemia |
| Blastic Phase |
| Recurrent Adult Acute Lymphoblastic Leukemia |
| Recurrent Adult Acute Myeloid Leukemia |
| Recurrent Disease |
| Untreated Adult Acute Lymphoblastic Leukemia |
Keywords: